Steps required to develop and validate novel end points as surrogates for disease-modifying potential in MF.
Figure 2.

Steps required to develop and validate novel end points as surrogates for disease-modifying potential in MF.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal